Federal investigators in Manhattan are examining an allegation made by GSK that Pfizer postponed revealing the success of its COVID-19 vaccine in 2020 until after the presidential election that year, according to the Wall Street Journal, which cited sources with knowledge of the situation.

On Wednesday, it was reported that Philip Dormitzer, who previously led vaccine development at GSK and joined the company after his tenure at Pfizer, informed his colleagues at GSK about this alleged delay.

However, Dormitzer has disputed that account.

“My team at Pfizer and I were committed to securing the FDA’s Emergency Use Authorization as quickly as possible. Any other interpretation of my comments regarding the vaccine development timeline would be inaccurate,” Dormitzer stated to Reuters.

The WSJ report said the US Attorney’s Office for the Southern District of New York, which includes Manhattan, is taking a closer look at what GSK has shared.

President Trump has claimed in the past that Pfizer sat on positive data from the vaccine’s clinical trials, but there has never been evidence to support the accusation.

The US attorney’s office in Manhattan has interviewed at least two people, including a GSK executive who took notes of a conversation with Dormitzer, the report said, citing one of the people familiar with the matter.

The prosecutors are planning to interview a third person in the coming days, WSJ reported, citing some of the people familiar with the probe.

The report said officials from Pfizer have not been interviewed.

GSK has declined to comment, while Pfizer and the US Attorney’s Office in Manhattan did not immediately respond to Reuters’ requests for comments.